Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

New lung cancer pathways discovered using computer modeling

New lung cancer pathways discovered using computer modeling

Combination of leukemia and breast cancer drugs inhibits cancer progression

Combination of leukemia and breast cancer drugs inhibits cancer progression

HemoRANK-TKI in vitro assay service package from ReachBio

HemoRANK-TKI in vitro assay service package from ReachBio

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

Identifying a specific molecular signature can help customize cancer treatment

Identifying a specific molecular signature can help customize cancer treatment

Discovery of genetic key to breast cancer's ability to survive and spread

Discovery of genetic key to breast cancer's ability to survive and spread

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

Therapeutic effect of imatinib improved with addition of chloroquine

Therapeutic effect of imatinib improved with addition of chloroquine

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

When less is more: Brief inhibition of cancer target is effective and less toxic

When less is more: Brief inhibition of cancer target is effective and less toxic

Researcher develops method for early detection of leukemia relapse

Researcher develops method for early detection of leukemia relapse

Bosutinib safe, effective for chronic myelogenous leukemia

Bosutinib safe, effective for chronic myelogenous leukemia

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

New role for miRNA in leukemia discovered

New role for miRNA in leukemia discovered

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Fingolimod shows promise in 2 lethal leukemias

Fingolimod shows promise in 2 lethal leukemias